We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · December 08, 2015

Progression on Multiple Lines of Therapy

Written by
Andrew Fintel DO

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • George Yaghmour

    Immunotherapy is good choice. However, considering the Good PS and CCRCC pathology would also consider Cabozantinib per Toni choueiri et al NEJM article.


  • George Yaghmour

    Given the good PS and the extent of disease. Considering SBRT and debunking recurrent disease then consider further treatment. Also the updated results from expanded cohorts in CheckMate 016 confirmed initial safety findings and promising anti tumor activity for nivolumab + ipilimumab in patients with metastatic renal cell carcinoma. Overall survival for the combination in metastatic renal cell carcinoma is encouraging.


  • Angel Rodriguez

    Another option is retreatment with the best tki used previously


  • Oct 31, 2020

    Pending Moderator approval.
    Delete

Further Reading